Levi & Korsinsky is investigating potential claims on behalf of purchasers of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NasdaqCM: MDXG) stock.
For more information, click here: http://zlk.9nl.com/mimedx-mdxg/.
On September 4, 2013, MiMedx confirmed that it had received a letter from the Food and Drug Administration indicating that the Company’s Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing drugs at one of its plants, thereby manufacturing and marketing unapproved biologics products. Upon this news MiMedx stock fell from a close of $6.06 per share the previous day, to a close of $3.85 per share on September 4, 2013.
If you own MiMedx stock and wish to obtain additional information about the investigation and your legal rights please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/mimedx-mdxg/.Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.